Skip to content
Menu

Beam Therapeutics Inc. BEAM

Full chart Compare
Set alert

Price alert · BEAM

All alert types
20.90 USD -0.04 (-0.19%)

Regular-session close

21.66 +0.76 +3.65%

After hours · Nov 20, 6:53 PM ET

20.54 Day range 22.10
20.60 52-week range 37.92
YTD
-24.60%
1 year
+1.46%

5D -1.74 (-7.69%)

2122MonTueWedThuFri20.90
Market cap
2.16B
Revenue (ttm)
146.64M
Profit margin
-73.89%
EPS (ttm)
-0.87
Shares out
103.50M
Forward P/E
-4.05
YTD return
-24.60%
1-year return
+1.46%
50-day average
24.70
200-day average
27.74
Volume
3.89M
Avg volume
2.02M
Open
20.54
Previous close
20.94
Day's range
20.54 – 22.10
52-week range
20.60 – 37.92
Beta
2.22
Analysts
Strong Buy
Price target
49.85 (+138.5%)
Earnings date
Feb 23, 2027

Key statistics

Enterprise value
1.29B
Price / sales
14.75
Price / book
2.19
Revenue growth
-96.80%
Free cash flow
-262.63M
Total cash
1.04B
Total debt
243.87M
Return on equity
-11.29%
Short % of float
38.92%

Fundamental scorecard

9 of 25 checks passed on BEAM’s reported financials

ValueGrowthProfitabilityHealthDividend

9of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
BEAM Revenue — quarterly 307.00K
BEAM Net income — quarterly -134.41M
BEAM EPS — quarterly -1.28

Earnings

BEAM recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 2026-1.28———
Nov 3, 2026Sep 30, 2026-1.15-1.28-0.13-11.30%
Aug 4, 2026Jun 30, 2026-1.11-1.18-0.07-6.31%
May 7, 2026Mar 31, 2026-0.87-0.91-0.04-4.60%
Feb 24, 2026Dec 31, 2025-1.13-0.10+1.03+91.15%
Nov 4, 2025Sep 30, 2025-0.98-1.10-0.12-12.24%

Upgrades / downgrades

BEAM analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026WedbushmainOutperformOutperform
Nov 5, 2026GuggenheimmainBuyBuy
Nov 4, 2026Canaccord GenuitymainBuyBuy
Nov 4, 2026WedbushmainOutperformOutperform
Oct 29, 2026Canaccord GenuitymainBuyBuy
Oct 28, 2026WedbushmainOutperformOutperform

About Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
beamtx.com

News

Your note

Sign in to keep a note on BEAM — it syncs with the Stock Master app.

Insider holders

BEAM insider holders
InsiderRelationLatest transactionDateShares held
BELLON CHRISTINEOfficerSaleMar 31, 2026109,711
CAVANAGH BETHANY JOfficer and TreasurerSaleMar 31, 202651,171
CIARAMELLA GIUSEPPEPresidentConversion of Exercise of derivative securityJun 16, 2026253,911
EMANY SRAVAN KUMARChief Financial OfficerStock Award(Grant)Mar 30, 2026105,456
EVANS JOHN M.Chief Executive OfficerSaleJun 29, 20261,150,200
FMR, L.L.C.Beneficial Owner of more than 10% of a Class of SecuritySaleJun 25, 20260

Institution ownership

BEAM institution ownership
Holder% heldSharesValueReported
FMR, LLC12.49%12,926,476270.16MSep 29, 2026
ARK Investment Management, LLC11.41%11,805,372246.73MSep 29, 2026
Farallon Capital Management LLC9.93%10,276,396214.78MSep 29, 2026
Blackrock Inc.8.81%9,119,097190.59MSep 29, 2026
State Street Corporation5.72%5,920,492123.74MSep 29, 2026
Vanguard Portfolio Management LLC4.74%4,901,651102.44MSep 29, 2026

Fund ownership

BEAM fund ownership
Holder% heldSharesValueReported
ARK ETF Trust-ARK Innovation ETF6.00%6,207,008129.73MOct 30, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund3.34%3,457,34772.26MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF3.33%3,441,42071.93MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.16%3,273,30768.41MJun 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF2.98%3,086,45064.51MOct 30, 2026
iShares Trust-iShares Russell 2000 ETF2.48%2,569,27653.70MSep 29, 2026